GENENTECH & INOTEK ENTER INTO EXCLUSIVE GLOBAL STRATEGIC ALLIANCE FOR THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF PARP INHIBITORS FOR CANCER

Genentech, Inc. and Inotek Pharmaceuticals Corporation announced that they have entered into an exclusive global collaboration to discover, develop, manufacture and commercialize inhibitors of poly (ADP-ribose) polymerase (PARP) for the potential treatment of cancer. PARP is a nuclear enzyme within cells that directs the repair of damaged DNA via the activation and recruitment of DNA repair enzymes and has applications for the treatment of oncology and cardiovascular conditions. Biotech Intelligence (http://www.biotech-intelligence.com/html/html/pool_3/e29fc10da6e8fd9013c80e4171bd32dd.html)